Filing Details
- Accession Number:
- 0000947871-21-000844
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-07-30 18:20:35
- Reporting Period:
- 2021-07-28
- Accepted Time:
- 2021-07-30 18:20:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1739174 | Biomx Inc. | PHGE | () | L3 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1569590 | Ltd. Gp Israel Orbimed | 89 Medinat Hayehudim St., Building E Herzilya L3 4614001 | No | No | Yes | No | |
| 1569821 | Partnership Limited Gp Biofund Israel Orbimed | 89 Medinat Hayehudim St., Building E Herzilya L3 4614001 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 Par Value | Acquisiton | 2021-07-28 | 500,000 | $0.00 | 2,813,489 | No | 4 | P | Indirect | See Footnotes |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | See Footnotes |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Warrants (Right to Buy) | Acquisiton | 2021-07-28 | 375,000 | $0.00 | 375,000 | $5.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 375,000 | 2022-01-28 | 2027-01-28 | No | 4 | P | Indirect |
Footnotes
- In the Issuer's underwritten public offering, OrbiMed Israel Partners Limited Partnership ("OIP") purchased units that included 500,000 shares of the Issuer's common stock and 375,000 warrants, each exercisable for 1 share of the Issuer's common stock. The purchase price of each unit was $4.00.
- The purchase reported on this Form 4 were made by OIP. Following the transactions reported on this Form 4, OIP LP is the direct owner of 2,172,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of OIP and OII. By virtue of these relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and OII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Nissim Darvish, Anat Naschitz, and Erez Chimovits.
- This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Billionaire Hedge Funds
